HH Biotechnology Holdings Company (HHBT)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HH Biotechnology Holdings Company (HHBT) ist im Real Estate-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 50/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026HH Biotechnology Holdings Company (HHBT) Immobilienportfolio & Strategie
HH Biotechnology Holdings Company, operating in the real estate services sector, cultivates and supplies macadamia nuts for diverse applications. With a 31.0% profit margin, the company focuses on health and green industries, distinguishing itself through its agricultural focus within the real estate landscape.
Investmentthese
HH Biotechnology Holdings Company presents a unique investment proposition within the real estate services sector due to its focus on macadamia nut cultivation. The company's 31.0% profit margin indicates operational efficiency, while its 29.5% gross margin reflects the profitability of its core business. Key value drivers include the increasing demand for macadamia nuts in various industries and the company's established presence in the Chinese market. Potential catalysts include expansion into new geographic regions and diversification of product offerings. However, investors may want to evaluate the high beta of 4.45, indicating significant volatility, and the absence of dividends, which may deter income-seeking investors. The company's success hinges on its ability to scale production, manage costs, and navigate the competitive landscape.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Profit Margin of 31.0% indicates strong operational efficiency.
- Gross Margin of 29.5% reflects the profitability of macadamia nut cultivation.
- Beta of 4.45 suggests high volatility compared to the market.
- Focus on health and green industries aligns with growing consumer trends.
- Headquartered in Shenyang, China, providing access to a large and growing market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Profit Margin of 31.0%.
Schwaechen
- High beta of 4.45.
- Lack of dividend payments.
- Limited geographic diversification.
- Small number of employees (121).
Katalysatoren
- Upcoming: Potential expansion into international markets within 2-3 years.
- Upcoming: Diversification of product offerings within 1-2 years.
- Ongoing: Strategic partnerships with food and cosmetic companies within 1 year.
- Ongoing: Investment in research and development to improve macadamia nut yields.
- Ongoing: Implementation of sustainable farming practices to reduce environmental impact.
Risiken
- Potential: Competition from larger agricultural companies.
- Potential: Fluctuations in macadamia nut prices.
- Potential: Changes in consumer preferences.
- Potential: Economic downturns.
- Ongoing: Limited financial disclosure due to OTC Other listing.
Wachstumschancen
- Expansion into international markets: HH Biotechnology Holdings Company can explore opportunities to export macadamia nuts to countries with high demand for healthy snacks and plant-based ingredients. The global macadamia market is projected to reach $2.15 billion by 2028, presenting a significant growth opportunity. Timeline: 2-3 years.
- Diversification of product offerings: The company can expand its product line to include macadamia nut-based products such as macadamia oil, macadamia butter, and macadamia flour. This diversification can cater to a wider range of consumer preferences and increase revenue streams. The market for plant-based products is growing rapidly, with a projected value of $74.2 billion by 2027. Timeline: 1-2 years.
- Strategic partnerships with food and cosmetic companies: HH Biotechnology Holdings Company can collaborate with food and cosmetic manufacturers to supply macadamia nuts for their products. These partnerships can provide a stable demand for the company's macadamia nuts and increase its market reach. The food and cosmetic industries are increasingly seeking natural and sustainable ingredients, creating opportunities for macadamia nut suppliers. Timeline: 1 year.
- Investment in research and development: The company can invest in research and development to improve macadamia nut yields, develop new macadamia nut varieties, and enhance the quality of its products. This can provide a competitive advantage and increase the value of its macadamia nuts. The agricultural technology market is growing rapidly, with a projected value of $30.9 billion by 2025. Timeline: Ongoing.
- Implementation of sustainable farming practices: HH Biotechnology Holdings Company can adopt sustainable farming practices to reduce its environmental impact and appeal to environmentally conscious consumers. This can enhance the company's reputation and attract customers who prioritize sustainability. The market for sustainable products is growing rapidly, with a projected value of $150 billion by 2021. Timeline: Ongoing.
Chancen
- Expansion into international markets.
- Diversification of product offerings.
- Strategic partnerships with food and cosmetic companies.
- Investment in research and development.
Risiken
- Competition from larger agricultural companies.
- Fluctuations in macadamia nut prices.
- Changes in consumer preferences.
- Economic downturns.
Wettbewerbsvorteile
- Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Potential for sustainable farming practices.
Ueber HHBT
HH Biotechnology Holdings Company, originally incorporated in 1987 as Great China International Holdings, Inc., transitioned to its current name in August 2016 to reflect its focus on health and green industries. Headquartered in Shenyang, People's Republic of China, the company specializes in the cultivation and supply of macadamia nuts. These nuts are utilized across various sectors, including food, cooking oils, healthy products, toiletries, and cosmetics. The company's operations are centered around providing high-quality macadamia nuts to meet the growing demand for natural and healthy ingredients. With 121 employees, HH Biotechnology Holdings Company aims to capitalize on the increasing consumer interest in health-conscious products and sustainable practices. The company's strategic shift towards macadamia nut production positions it within the broader agricultural sector, aligning with the rising global demand for plant-based ingredients and natural resources.
Was das Unternehmen tut
- Cultivates macadamia nuts.
- Supplies macadamia nuts to food manufacturers.
- Provides macadamia nuts for cooking oil production.
- Offers macadamia nuts for healthy product formulations.
- Supplies macadamia nuts for toiletries and cosmetics.
- Focuses on health and green industries.
Geschaeftsmodell
- Cultivation and harvesting of macadamia nuts.
- Sale of macadamia nuts to various industries.
- Revenue generation through product sales.
- Focus on sustainable and environmentally friendly practices.
Branchenkontext
HH Biotechnology Holdings Company operates within the real estate services sector, with a specific focus on agricultural activities related to macadamia nut production. The global macadamia market is experiencing growth driven by increasing demand for healthy snacks, plant-based ingredients, and natural cosmetics. The competitive landscape includes agricultural companies, food producers, and cosmetic manufacturers. HH Biotechnology Holdings Company differentiates itself through its specialization in macadamia nuts and its presence in the Chinese market. The company's success depends on its ability to compete with larger agricultural players and capitalize on the growing demand for macadamia nuts in various industries.
Wichtige Kunden
- Food manufacturers.
- Cooking oil producers.
- Healthy product companies.
- Toiletries and cosmetics manufacturers.
Finanzdaten
Chart & Info
HH Biotechnology Holdings Company (HHBT) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Friday
· 28. Feb. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HHBT.
Kursziele
Wall-Street-Kurszielanalyse fuer HHBT.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von HHBT auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Sheng Jiang
CEO
Sheng Jiang is the CEO of HH Biotechnology Holdings Company, overseeing the company's operations in the health and green industries. His background includes experience in managing teams and driving strategic initiatives. He is responsible for the company's overall performance and growth. With a focus on sustainable practices and innovation, Sheng Jiang aims to position HH Biotechnology Holdings Company as a leader in the macadamia nut industry.
Erfolgsbilanz: Under Sheng Jiang's leadership, HH Biotechnology Holdings Company has focused on expanding its macadamia nut cultivation and supply operations. Key milestones include increasing production capacity and establishing partnerships with food and cosmetic companies. His strategic decisions have contributed to the company's growth and profitability. He manages 121 employees.
HHBT OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that HH Biotechnology Holdings Company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risks due to the lack of regulatory oversight and transparency.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Lack of regulatory oversight.
- Potential for fraud and manipulation.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has been in business since 1987.
- Focus on a specific niche market (macadamia nuts).
- Presence of a CEO (Sheng Jiang).
- 121 employees suggest some scale of operations.
- Profit margin of 31.0% indicates some financial viability.
HHBT Real Estate Aktien-FAQ
What are the key factors to evaluate for HHBT?
HH Biotechnology Holdings Company (HHBT) currently holds an AI score of 50/100, indicating moderate score. Key strength: Specialization in macadamia nut cultivation.. Primary risk to monitor: Potential: Competition from larger agricultural companies.. This is not financial advice.
How frequently does HHBT data refresh on this page?
HHBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HHBT's recent stock price performance?
Recent price movement in HH Biotechnology Holdings Company (HHBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialization in macadamia nut cultivation.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HHBT overvalued or undervalued right now?
Determining whether HH Biotechnology Holdings Company (HHBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HHBT?
Before investing in HH Biotechnology Holdings Company (HHBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HHBT to a portfolio?
Potential reasons to consider HH Biotechnology Holdings Company (HHBT) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialization in macadamia nut cultivation.. Additionally: Established presence in the Chinese market.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of HHBT?
Yes, most major brokerages offer fractional shares of HH Biotechnology Holdings Company (HHBT) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HHBT's earnings and financial reports?
HH Biotechnology Holdings Company (HHBT) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HHBT earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- AI analysis pending for HHBT.
- Limited information available on OTC Other stocks.